IDH1/IDH2 Mutation Analysis by PCR
Also known as: IDH1 Mutation Analysis, IDH2 Mutation Analysis
Use
Mutations in the enzyme isocitrate dehydrogenase 1 (IDH1) and IDH2 genes have been identified in a variety of tumors including central nervous system gliomas, cholangiocarcinoma, acute myeloid leukemia, blast-phase myeloproliferative neoplasms (MPNs) and chronic-phase primary myelofibrosis (PMF). Per professional practice guidelines, testing for IDH mutations has diagnostic and prognostic implications in the workup of gliomas and guides therapy selection in AML. AML patients with IDH mutations may respond to venetoclax-based therapy or IDH inhibitors.
Special Instructions
Not provided.
Limitations
Do not use zinc fixatives. If submitting slides, use positively-charged slides and 10% NBF fixative. Block and slide identifiers must be clearly written and match the specimen ID and labeling as noted on the requisition.
New York Approved
Methodology
PCR-based (RT-PCR)
Biomarkers
IDH1, IDH2
Gene
Result Turnaround Time
5 days
Related Documents
For more information, please review the documents below
Specimen
Bone Marrow
Volume
2 mL
Minimum Volume
Not provided
Container
EDTA tube